Clinical review report: Cysteamine delayed-release capsules (Procysbi) Horizon Pharma Ireland Ltd
The objective of this review is to perform a systematic review of the beneficial and harmful effects of delayed-release cysteamine (Procysbi [RP103])
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, February 2018
|
Edition: | Version: final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of delayed-release cysteamine (Procysbi [RP103]) |
---|---|
Item Description: | "Indication: For the treatment of nephropathic cystinosis." |
Physical Description: | 1 PDF file (67 pages) illustrations |